Millions of people around the world suffer from gastrointestinal issues like gastroparesis, reflux, and constipation, but until now, the available treatments haven’t been very effective, and often carry some pretty nasty potential side effects. Today, we're featuring a company hoping to bring those people relief with a drug that's both efficacious and safe. Today's guest is Peter Milner, the founder and managing member of Renexxion, where he serves as the CEO of its wholly owned operating subsidiary, Renexxion Ireland Limited, a clinical stage biopharma company committed to delivering innovative drugs to patients with gastrointestinal disorders globally. Peter’s a board-certified cardiologist, a physician-scientist and a serial entrepreneur with a proven track record of building successful biotechnology companies, including CV Therapeutics and Aptivio Biotechnology, and advancing novel therapeutics from discovery to development. Today, Peter’s going to walk us through Renexxion’s very promising new drug, the treatment gap it aims to redress, and what it will take to get it through clinical trials and into the hands of patients. Highlights:From Medicine to Serial Entrepreneur (3:00)The Gap in GI Treatment (3:30)How the Drug Works (6:10)Where Others Failed (5:05)Trial Results and the Road to Phase 3 (8:20)The Problem with Current Treatments (9:45)The Dr. Falk Partnership (17:10)Pipeline in a Pill (20:20)The Billion-Dollar Opportunity (21:45)What's Next for Renexxion (23:50)Links:Peter Milner LinkedInRenexxion LinkedInRenexxion WebsiteICR LinkedInICR TwitterICR Website Feedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, [email protected]

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related